Emergent BioSolutions (FRA:ER4) Institutional Ownership: 55.98% (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ER4 Emergent BioSolutions Inc FRA:ER4
61 GF Score
Price €6.54
GF Value €4.15
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Institutional Ownership?

Emergent BioSolutions FRA:ER4 +2.19% 61 Institutional Ownership is 55.98% as of Aug. 06, 2026. GuruFocus rates FRA:ER4 with a GF Score™ of 61/100 and a GF Value™ of €4.15 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Emergent BioSolutions's institutional ownership is 55.98%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Emergent BioSolutions's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Emergent BioSolutions's Float Percentage Of Total Shares Outstanding is 98.44%.

Emergent BioSolutions Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Institutional Ownership Chart

Emergent BioSolutions Historical Data

The historical data trend for Emergent BioSolutions can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 44.60 45.16 45.39 45.59 46.18 50.48 51.53 52.39 54.79 55.98
FRA:ER4
61GF Score
Emergent BioSolutions Inc FRA:ER4
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 55.98% mean?
Emergent BioSolutions (FRA:ER4) has a Institutional Ownership of 55.98% as of Aug. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Institutional Ownership too high?
Emergent BioSolutions' current Institutional Ownership is 55.98%. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Institutional Ownership compare to EOLS and ELTP?
Emergent BioSolutions' Institutional Ownership of 55.98% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Institutional Ownership is 55.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (FRA:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €6.54 — trading 57.5% above its estimated fair value. The current Institutional Ownership is 55.98%. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Emergent BioSolutions (FRA:ER4), the current Institutional Ownership is 55.98% as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (FRA:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €6.54 is trading 57.5% above its estimated GF Value™ of €4.15. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for FRA:ER4:

  • Institutional Ownership: 55.98%
  • GF Value™: €4.15 vs. price of €6.54 (57.5% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the FRA:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UKER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score

Get the complete analysis for FRA:ER4

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.54
Price
€4.15
GF Value